'Surprise' Phase III failure of GW/Otsuka's Sativex in cancer pain
This article was originally published in Scrip
GW Pharmaceuticals is reeling on news that its cannabinoid-derived product Sativex has failed the first of three Phase III trials in the treatment of cancer pain. Sativex is licensed to Otsuka in the US where cancer pain is the lead indication. Data from the three trials were to form the basis of the first NDA filing for Sativex in the US.